Development and Validation of an Analytical Procedure for Determining Convallatoxin in Medicinal Products Containing Cardiac Glycosides of Lily of the Valley

INTRODUCTION. The safe use of lily-of-the-valley medicinal products requires adequately controlling the content of cardiac glycosides. The State Pharmacopoeia of the Russian Federation stipulates that the content of cardiac glycosides in lily-of-the-valley medicinal products should be quantified usi...

Full description

Saved in:
Bibliographic Details
Main Authors: T. A. Golomazova, N. P. Antonova, N. E. Semenova, E. P. Shefer, S. S. Prokhvatilova
Format: Article
Language:Russian
Published: Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’) 2024-11-01
Series:Регуляторные исследования и экспертиза лекарственных средств
Subjects:
Online Access:https://www.vedomostincesmp.ru/jour/article/view/714
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849249573751488512
author T. A. Golomazova
N. P. Antonova
N. E. Semenova
E. P. Shefer
S. S. Prokhvatilova
author_facet T. A. Golomazova
N. P. Antonova
N. E. Semenova
E. P. Shefer
S. S. Prokhvatilova
author_sort T. A. Golomazova
collection DOAJ
description INTRODUCTION. The safe use of lily-of-the-valley medicinal products requires adequately controlling the content of cardiac glycosides. The State Pharmacopoeia of the Russian Federation stipulates that the content of cardiac glycosides in lily-of-the-valley medicinal products should be quantified using bioassays and spectrophotometry. However, the determination of cardiac glycosides needs more accurate and selective physicochemical methods, such as high-performance liquid chromatography (HPLC).AIM. This study aimed to develop and validate an HPLC analytical procedure for the quantitative determination of cardiac glycosides (convallatoxin) in lily-of-the-valley herbal medicinal products.MATERIALS AND METHODS. The study examined the Lily-of-the-Valley Tincture, Zelenin Drops, Valocormid, Carniland®, and Lily-of-the-Valley Extract Reference Standard samples. The content of cardiac glycosides was determined by comparison with a reference standard for convallatoxin by HPLC and spectrophotometry. The samples were prepared as outlined in Monograph 3.4.0003.18 Lily-of-the-Valley Herb Tincture of the State Pharmacopoeia of the Russian Federation. Mixed cardiac glycosides were separated on a Luna 5 µm C18(2) column by gradient elution with 0.1% orthophosphoric acid in water and acetonitrile. The analysis was performed using an autoinjector with sample cooling to 5 °C.RESULTS. The developed analytical procedure met the acceptance criteria for specificity, intermediate precision, linearity (correlation coefficient of 0.99985), and repeatability (relative standard deviation of convallatoxin measurements of 1.61%). The analytical procedure is suitable for the quantitative determination of convallatoxin in lily-of-the-valley herbal medicinal products because it produces reliable and repeatable results.CONCLUSIONS. The authors developed a highly sensitive and selective HPLC analytical procedure for the quantitative determination of convallatoxin in lily-of-the-valley herbal medicinal products. The content of convallatoxin ranged from 0.012 to 0.018 mg/mL in the liquid active substance Lily-of-the-Valley Tincture, from 0.004 to 0.013 mg/mL in the medicinal product Zelenin Drops, and from 0.005 to 0.007 mg/mL in the medicinal products Carniland® and Valocormid. For the Lily-of-the-Valley Extract Reference Standard, the content of convallatoxin amounted to 0.029 mg/mL.
format Article
id doaj-art-e3db2c025810466d8a427c489d9529e7
institution Kabale University
issn 3034-3062
3034-3453
language Russian
publishDate 2024-11-01
publisher Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)
record_format Article
series Регуляторные исследования и экспертиза лекарственных средств
spelling doaj-art-e3db2c025810466d8a427c489d9529e72025-08-20T03:57:31ZrusFederal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)Регуляторные исследования и экспертиза лекарственных средств3034-30623034-34532024-11-0114558058910.30895/1991-2919-2024-14-5-580-589473Development and Validation of an Analytical Procedure for Determining Convallatoxin in Medicinal Products Containing Cardiac Glycosides of Lily of the ValleyT. A. Golomazova0N. P. Antonova1N. E. Semenova2E. P. Shefer3S. S. Prokhvatilova4Scientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsINTRODUCTION. The safe use of lily-of-the-valley medicinal products requires adequately controlling the content of cardiac glycosides. The State Pharmacopoeia of the Russian Federation stipulates that the content of cardiac glycosides in lily-of-the-valley medicinal products should be quantified using bioassays and spectrophotometry. However, the determination of cardiac glycosides needs more accurate and selective physicochemical methods, such as high-performance liquid chromatography (HPLC).AIM. This study aimed to develop and validate an HPLC analytical procedure for the quantitative determination of cardiac glycosides (convallatoxin) in lily-of-the-valley herbal medicinal products.MATERIALS AND METHODS. The study examined the Lily-of-the-Valley Tincture, Zelenin Drops, Valocormid, Carniland®, and Lily-of-the-Valley Extract Reference Standard samples. The content of cardiac glycosides was determined by comparison with a reference standard for convallatoxin by HPLC and spectrophotometry. The samples were prepared as outlined in Monograph 3.4.0003.18 Lily-of-the-Valley Herb Tincture of the State Pharmacopoeia of the Russian Federation. Mixed cardiac glycosides were separated on a Luna 5 µm C18(2) column by gradient elution with 0.1% orthophosphoric acid in water and acetonitrile. The analysis was performed using an autoinjector with sample cooling to 5 °C.RESULTS. The developed analytical procedure met the acceptance criteria for specificity, intermediate precision, linearity (correlation coefficient of 0.99985), and repeatability (relative standard deviation of convallatoxin measurements of 1.61%). The analytical procedure is suitable for the quantitative determination of convallatoxin in lily-of-the-valley herbal medicinal products because it produces reliable and repeatable results.CONCLUSIONS. The authors developed a highly sensitive and selective HPLC analytical procedure for the quantitative determination of convallatoxin in lily-of-the-valley herbal medicinal products. The content of convallatoxin ranged from 0.012 to 0.018 mg/mL in the liquid active substance Lily-of-the-Valley Tincture, from 0.004 to 0.013 mg/mL in the medicinal product Zelenin Drops, and from 0.005 to 0.007 mg/mL in the medicinal products Carniland® and Valocormid. For the Lily-of-the-Valley Extract Reference Standard, the content of convallatoxin amounted to 0.029 mg/mL.https://www.vedomostincesmp.ru/jour/article/view/714cardiac glycosidesconvallatoxinhigh-performance liquid chromatographyhplclily-of-the-valley herbherbal medicinal productszelenin drops
spellingShingle T. A. Golomazova
N. P. Antonova
N. E. Semenova
E. P. Shefer
S. S. Prokhvatilova
Development and Validation of an Analytical Procedure for Determining Convallatoxin in Medicinal Products Containing Cardiac Glycosides of Lily of the Valley
Регуляторные исследования и экспертиза лекарственных средств
cardiac glycosides
convallatoxin
high-performance liquid chromatography
hplc
lily-of-the-valley herb
herbal medicinal products
zelenin drops
title Development and Validation of an Analytical Procedure for Determining Convallatoxin in Medicinal Products Containing Cardiac Glycosides of Lily of the Valley
title_full Development and Validation of an Analytical Procedure for Determining Convallatoxin in Medicinal Products Containing Cardiac Glycosides of Lily of the Valley
title_fullStr Development and Validation of an Analytical Procedure for Determining Convallatoxin in Medicinal Products Containing Cardiac Glycosides of Lily of the Valley
title_full_unstemmed Development and Validation of an Analytical Procedure for Determining Convallatoxin in Medicinal Products Containing Cardiac Glycosides of Lily of the Valley
title_short Development and Validation of an Analytical Procedure for Determining Convallatoxin in Medicinal Products Containing Cardiac Glycosides of Lily of the Valley
title_sort development and validation of an analytical procedure for determining convallatoxin in medicinal products containing cardiac glycosides of lily of the valley
topic cardiac glycosides
convallatoxin
high-performance liquid chromatography
hplc
lily-of-the-valley herb
herbal medicinal products
zelenin drops
url https://www.vedomostincesmp.ru/jour/article/view/714
work_keys_str_mv AT tagolomazova developmentandvalidationofananalyticalprocedurefordeterminingconvallatoxininmedicinalproductscontainingcardiacglycosidesoflilyofthevalley
AT npantonova developmentandvalidationofananalyticalprocedurefordeterminingconvallatoxininmedicinalproductscontainingcardiacglycosidesoflilyofthevalley
AT nesemenova developmentandvalidationofananalyticalprocedurefordeterminingconvallatoxininmedicinalproductscontainingcardiacglycosidesoflilyofthevalley
AT epshefer developmentandvalidationofananalyticalprocedurefordeterminingconvallatoxininmedicinalproductscontainingcardiacglycosidesoflilyofthevalley
AT ssprokhvatilova developmentandvalidationofananalyticalprocedurefordeterminingconvallatoxininmedicinalproductscontainingcardiacglycosidesoflilyofthevalley